Ratings Epigenomics AG Deutsche Boerse AG

Equities

End-of-day quote Deutsche Boerse AG Other stock markets 18:00:00 2024-02-04 EST			5-day change	1st Jan Change
1.785 ^EUR	-1.92%		+9.51%	-4.03%

03-14

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company's share price in relation to its net book value makes it look relatively cheap.
The company has a low valuation given the cash flows generated by its activity.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
EPIGENOMICS AG	-4.03%	1.49M		-
EXACT SCIENCES CORPORATION	-18.88%	10.91B		A-
IOVANCE BIOTHERAPEUTICS, INC.	+53.75%	3.3B		D+
GUARDANT HEALTH, INC.	-32.50%	2.19B		C
BGI GENOMICS CO., LTD.	-14.31%	2.16B	-	B-
VERACYTE, INC.	-26.83%	1.5B		C+
MARAVAI LIFESCIENCES HOLDINGS, INC.	+28.55%	1.09B		B-
SEEGENE, INC.	-3.28%	737M		C+
CAREDX, INC	-23.50%	404M		C-
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-43.27%	386M		C-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality